Cargando…

Modeling restoration of gefitinib efficacy by co‐administration of MET inhibitors in an EGFR inhibitor‐resistant NSCLC xenograft model: A tumor‐in‐host DEB‐based approach

MET receptor tyrosine kinase inhibitors (TKIs) can restore sensitivity to gefitinib, a TKI targeting epidermal growth factor receptor (EGFR), and promote apoptosis in non‐small cell lung cancer (NSCLC) models resistant to gefitinib treatment in vitro and in vivo. Several novel MET inhibitors are cur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tosca, Elena M., Gauderat, Glenn, Fouliard, Sylvain, Burbridge, Mike, Chenel, Marylore, Magni, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592518/ https://www.ncbi.nlm.nih.gov/pubmed/34708556 http://dx.doi.org/10.1002/psp4.12710

Ejemplares similares

How to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an Example
por: Meyer, Claudia, et al.
Publicado: (2022)

Influence of the Duration of Intravenous Drug Administration on Tumor Uptake
por: Fouliard, Sylvain, et al.
Publicado: (2013)

A Dynamic Energy Budget (DEB) based modeling framework to describe tumor-in-host growth inhibition and cachexia onset during anticancer treatment in in vivo xenograft studies
por: Tosca, Elena Maria, et al.
Publicado: (2021)

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
por: Liam, Chong Kin, et al.
Publicado: (2023)

Mechanistic Modeling of the Interplay Between Host Immune System, IL-7 and UCART19 Allogeneic CAR-T Cells in Adult B-cell Acute Lymphoblastic Leukemia
por: Derippe, Thibaud, et al.
Publicado: (2022)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
por: Presutti, Dario, et al.
Publicado: (2015)

Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models
por: Qu, Yiqing, et al.
Publicado: (2014)

Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models
por: Lubet, Ronald A., et al.
Publicado: (2018)

Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models
por: Lubet, Ronald A., et al.
Publicado: (2019)

Development of a Physiologically-Based Pharmacokinetic Model of the Rat Central Nervous System
por: Badhan, Raj K. Singh, et al.
Publicado: (2014)

Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization
por: Schueler, Julia, et al.
Publicado: (2019)

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
por: Wang, Kaiwen, et al.
Publicado: (2023)

A simple DEB-based ecosystem model
por: van der Meer, Jaap, et al.
Publicado: (2022)

HIF-1 Inhibitor YC-1 Reverses the Acquired Resistance of EGFR-Mutant HCC827 Cell Line with MET Amplification to Gefitinib
por: Jin, Qian, et al.
Publicado: (2021)

Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
por: Nanjo, Shigeki, et al.
Publicado: (2013)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations
por: Song, Ruiqiang, et al.
Publicado: (2022)

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
por: Masuda, Chinami, et al.
Publicado: (2017)

The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations
por: Xin, Shuang, et al.
Publicado: (2015)

Biphasic function of GSK3β in gefitinib‑resistant NSCLC with or without EGFR mutations
por: Li, Junzhe, et al.
Publicado: (2023)

Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification
por: La Monica, Silvia, et al.
Publicado: (2013)

Targeting the COX2/MET/TOPK signaling axis induces apoptosis in gefitinib-resistant NSCLC cells
por: Xiao, Juanjuan, et al.
Publicado: (2019)

Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC
por: Jie, Guang-Ling, et al.
Publicado: (2023)

Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer Development in a Xenograft Model
por: Sun, Yinggang, et al.
Publicado: (2015)

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status
por: Douillard, Jean-Yves, et al.
Publicado: (2014)

Involvement of SNX1 in regulating EGFR endocytosis in a gefitinib-resistant NSCLC cell lines
por: Nishimura, Yukio, et al.
Publicado: (2019)

RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC
por: Nishio, Makoto, et al.
Publicado: (2022)

Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC
por: Nigro, Annunziata, et al.
Publicado: (2020)

Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation
por: Cai, Boning, et al.
Publicado: (2021)

Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
por: He, Qihua, et al.
Publicado: (2021)

Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib
por: He, Peng, et al.
Publicado: (2013)

Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020)

Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC
por: Lin, Chien-Chung, et al.
Publicado: (2021)

BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
por: Karachaliou, Niki, et al.
Publicado: (2020)

The EGFR Inhibitor Gefitinib Enhanced the Response of Human Oral Squamous Cell Carcinoma to Cisplatin In Vitro
por: Khalil, Ashraf, et al.
Publicado: (2017)

Efficacy and safety of EGFR inhibitor gefitinib in recurrent or metastatic cervical cancer: a preliminary report
por: Krishna, Abhishek, et al.
Publicado: (2023)

Synergistic antitumor effects of cMet inhibitor in combination with anti-VEGF in colorectal cancer patient-derived xenograft models
por: Chen, Xiangheng, et al.
Publicado: (2018)

Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors
por: Sisi, Monia, et al.
Publicado: (2023)

The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models
por: Ribback, Silvia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_r1cpn4hb36525o63c7hq14c8js